Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has announced a collaboration agreement between its subsidiary Osteopore International and NASDAQ-listed biopharmaceutical company CytoMed Therapeutics.
NASDAQ-listed CytoMed is a Singapore-based biopharmaceutical company that seeks to leverage its proprietary technology to develop donor-derived cell-based allogeneic therapies for cancer and age-related degenerative diseases.
Recently, the company secured approval from Singapore’s Health Sciences Authority for a first-in-human donor allogeneic Phase 1 clinical trial with Singapore’s National University Hospital as principal investigator. In September 2024, CytoMed gained access to cord blood, a rare and expensive biomaterial with potential for regenerative medicine, by acquiring a cord blood banking license and assets.
Mesenchymal stem cells (MSCs) have demonstrated a strong clinical track record due to their mature isolation protocols, safety, and immunomodulatory properties. As research progresses, MSCs are emerging as a critical element in creating advanced therapies that enhance the body’s natural healing power. Their application demonstrates significant potential for transforming healthcare approaches to repairing damaged tissues and improving patient outcomes.
Under the scope of the 18-month agreement, Osteopore and CytoMed will set up a Technology Advisory Committee comprising one nominee from each party to assess co-development and resource utilisation opportunities. Subsequently, Osteopore and CytoMed may seek third-party funding to support growth and development opportunities in scaffold-based cell therapy.
Osteopore’s chairman, Mark Leong, said, “Together with our innovative scaffolds, MSCs will play a pivotal role in tissue repair, offering exceptional safety, accessibility, and the power to speed up healing and recovery. This is the future of tissue regeneration, where structural innovation meets cellular healing.
“The integration of CytoMed’s clinical-grade UC-MSCs with our scaffold technology, combined with our shared commitment to regenerative medicine, creates powerful synergies that can significantly enhance patient outcomes."